- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- AMAR REMEDIES
AMAR REMEDIES Share Price 
(AMAD)
Here is the latest stock price and chart of AMAR REMEDIES. For more details, see the AMAR REMEDIES company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Dec 11, 2013 (Close) | ||
|---|---|---|---|
| Price (Rs)6.07 | Open (Rs) 6.04 | High (Rs) 6.34 | Low (Rs) 5.74 |
| % Change0.50 | Volume 139,679 | Value (Rs) 854,123 | 52-Week H/L 48.00 / 5.48 |
| Live NSE Quotes | Dec 10, 2013 03:25:00 PM | ||
|---|---|---|---|
| Price (Rs)- | Open (Rs) 5.90 | High (Rs) 6.10 | Low (Rs) 5.80 |
| % Change-4.92 | Volume 60,361 | Value (Rs) 352,945 | 52-Week H/L 48.20 / 5.80 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* -12.04 | P/E Ratio (x) NM | Market Cap (Rs m) 158.79 | P/BV (x) 0.06 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX
PERIOD - Advanced Charts new
- Charts by TradingView
|
| |
Today's Market
Indian Indices Continue Sell-Off; Sensex Slumps Over 530 Points(Closing)
Share markets in India continued their sell-off seen during the last week and ended the day deep in the red. All sectoral indices traded on a negative note.
Related Views On News
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
Eris Lifesciences Limited (IPO)
Jun 15, 2017Exposure to high margin specialty products offers promising growth prospects.
Laurus Labs Ltd (IPO)
Dec 6, 2016Equitymaster analyses Initial Public Offering (IPO) of Laurus Labs, one of the leading supplier of APIs for ARVs and Hepatitis C.
More Views on NewsMost Popular
My First Pharma Stock Recommendation!(The 5 Minute Wrapup)
Sep 21, 2018This company has not only created a niche in the pharma space, it has done so profitably.
Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)
Sep 12, 2018Richa has discovered the single most profitable opportunity in the market - read on to discover more...
Are You Blindly Investing In Equities? Read This...(Outside View)
Sep 11, 2018PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.
Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)
Sep 12, 2018PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.
Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)
Sep 14, 2018Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.
MoreTRACK AMAR REMEDIES
- Track your investment in AMAR REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AMAR REMEDIES
AMAR REMEDIES - P&G COMPARISON
COMPARE AMAR REMEDIES WITH
OTHER USEFUL LINKS
MARKET STATS
|
| |
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.